Infl iximab for the treatment of plaque psoriasis

Biologics: Targets and Therapy

Volumn 2, Issue 1, 2008, Pages 115-124

  Gall, Jennifer S ^a   Kalb, Robert E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Infl iximab; Plaque; Psoriasis

Indexed keywords

EID: 80052627282     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Ahmad K, Rogers S. 2006. Three years' experience with infl iximab in recalcitrant psoriasis. Clin Exp Dermatol, 31:630-3
2. Anker SD, Coats AJS. 2002. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol, 86:123-30
3. Banno T, Gazel A, Blumenberg M. 2004. Effects of tumor necrosis factoralpha in epidermal keratinocytes revealed using global transcriptional profi ling. J Biol Chem, 279:32633-42
4. Behm BW, Bickston SJ. 2007. Effi cacy of infl iximab for luminal and fi stulizing Crohn's disease and in ulcerative colitis. Curr Treat Options Gastroenterol, 10:171-7
5. Centocor. 2007. Remicade [online]. Accessed 26 Nov 2007. www.remicade. com.
6. FDA. 2006. Biologic license application effi cacy supplements approved [online]. Accessed 15 June 2007. http://www.fda.gov.
7. Bongartz T, Sutton AJ, Sweeting MJ, et al. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 295:2275-85
8. Brown SL, Greene MH, Gershon SK, et al. 2002. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum, 46:3151-8
9. Callen JP. 2007. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg, 26:6-14
10. Cassano N, Loconsole F, Amoruso A, et al. 2004. Infl iximab monotherapy for refractory psoriasis: preliminary results. Int J Immunopathol Pharmacol, 17:373-80
11. Chan JJ, Gebauer K. 2003. Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infl iximab). Australas J Dermatol, 44:116-20
12. Chaudhari U, Romano P, Mulcahy LD, et al. 2001. Effi cacy and safety of infl iximab monotherapy for plaque-type psoriasis: a randomised trial. The Lancet, 357:1842-7
13. Chong BF, Wong HK. 2007. Immunobiologics in the treatment of psoriasis. Clin Immunol, 123:129-38
14. Chung ES, Packer M, Lo KH, et al. 2003a. Randomized, double-blind, placebo-controlled, pilot trial of infl iximab, a chimeric monoclonal antibody to tumor necrosis factor-{alpha}, in patients with moderate-tosevere heart failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial. Circulation, 107:3133-40
15. Chung ES, Packer M, Lo KH, et al. 2003b. Randomized, double-blind, placebo-controlled, pilot trial of infl iximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-tosevere heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation, 107:3133-40
16. Costa MF, Said NR, Zimmermann B. 2007. Drug-induced lupus due to anti-tumor necrosis factor agents. Semin Arthritis Rheum. Oct 29. [Epub ahead of print]
17. Elder JT, Nair RP, Henseler T, et al. 2001. The genetics of psoriasis 2001: the odyssey continues. Arch Dermatol, 137:1447-54
18. Ellerin T, Rubin RH, Weinblatt ME. 2003. Infections and anti-tumor necrosis factor therapy. Arthritis Rheum, 48:3013-22
19. Feldman AM, Combes A, Wagner D, et al. 2000. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol, 35:537-44
20. Feldman SR, Gordon KB, Bala M, et al. 2005. Infl iximab treatment results in signifi cant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol, 152:954-60
21. Gardam MA, Keystone EC, Menzies R, et al. 2003. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis, 3:148-55
22. Gelfand JM, Stern RS, Nijsten T, et al. 2005. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol, 52:23-6
23. Goedkoop AY, Kraan MC, Teunissen MBM, et al. 2004. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis, 63:769-73
24. Gottlieb AB. 2003. Infliximab for psoriasis. J Am Acad Dermatol, 49:112-7
25. Gottlieb AB, Chaudhari U, Mulcahy LD, et al. 2003. Infl iximab monotherapy provides rapid and sustained benefi t for plaque-type psoriasis. J Am Acad Dermatol, 48:829-35
26. Gottlieb AB, Evans R, Li S, et al. 2004. Infl iximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol, 51:534-42
27. Gottlieb AB, Masud S, Ramamurthi R, et al. 2003. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infl iximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol, 48:68-75
28. Haitz KA, Kalb RE. 2007. Infl iximab in the treatment of psoriasis in patients previously treated with etanercept. J Am Acad Dermatol, 57:120-5
29. MedWatch. 2004. Important drug warning [online]. Accessed 8 July 2007. URL: http://www.fda.gov.
30. Kalb RE, Gurske J. 2005. Infl iximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo. J Am Acad Dermatol, 53:616-22
31. Kaur N, Mahl T. 2007. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis and Sci, 52:1481-4
32. Keane J, Gershon S, Wise RP, et al. 2001. Tuberculosis associated with infl iximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med, 345:1098-104
33. Krathen RA, Berthelot CN, Hsu S. 2006. Sustained effi cacy and safety of infl iximab in psoriasis: a retrospective study of 73 patients. J Drugs Dermatol, 5:251-4
34. Krishnan RS, Hsu S. 2004. Serum sickness due to infl iximab in a patient with psoriasis. J Drugs Dermatol, 3:305-8
35. Krueger G, Koo J, Lebwohl M, et al. 2001. The impact of psoriasis on quality of life: results of a 1998 national psoriasis foundation patientmembership survey. Arch Dermatol, 137:280-4
36. Kruger-Krasagakis S, Galanopoulos VK, Giannikaki L, et al. 2006. Programmed cell death of keratinocytes in infl iximab-treated plaque-type psoriasis. Br J Dermatol, 154:460-6
37. Kwon HJ, Cote TR, Cuffe MS, et al. 2003. Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist. Ann Intern Med, 138:807-11
38. Langley RG, Gupta AK, Cherman AM, et al. 2007. Biologic therapeutics in the treatment of psoriasis. Part 1: review. J Cutan Med Surg, 11:99-122
39. Lebwohl M. 2003. Psoriasis. The Lancet, 361:1197-204
40. Markham, Mullan, Golden M, et al. 2006. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infl iximab therapy. Journal of the American Academy of Dermatology, 54:1003-12
41. Markham A, Lamb HM. 2000. Infl iximab: A review of its use in the management of rheumatoid arthritis. Drugs, 59:1341-59
42. Matzinger P. 2002. The danger model: a renewed sense of self. Science, 296:301-5
43. Menter A, Feldman SR, Weinstein GD, et al. 2007. A randomized comparison of continuous vs. intermittent infl iximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol, 56:31.e1-e15.
44. Mohan N, Edwards ET, Cupps TR, et al. 2001. Demyelination occurring during anti-tumor necrosis factor therapy for infl ammatory arthritides. Arthritis Rheum, 44:2862-9
45. National Psoriasis Foundation. 2007. About psoriasis: statistics [online]. Accessed 14 June 2007. www.psoriasis.org.
46. Nickoloff BJ. 1991. The cytokine network in psoriasis. Arch Dermatol, 127:871-84
47. Nickoloff BJ, Nestle FO. 2004. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest, 113:1664-75
48. Poulalhon N, Begon E, Lebbe C, et al. 2007. A follow-up study in 28 patients treated with infl iximab for severe recalcitrant psoriasis: evidence for effi cacy and high incidence of biological autoimmunity. Br J Dermatol, 156:329-36
49. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. 2007. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine, 86:242-51
50. Rapp SR, Feldman SR, Exum ML, et al. 1999. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol, 41:401-7
51. Reich K, Nestle FO, Papp K, et al. 2005. Infl iximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. The Lancet, 366:1367-74
52. Robinson WH, Genovese MC, Moreland LW. 2001. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum, 44:1977-83
53. Sauder DN, Mamelak AJ. 2004. Understanding the new clinical landscape for psoriasis: a comparative review of biologics. J Cutan Med Surg, 8:205-12
54. Schellekens H. 2002. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther, 24:1720-40
55. Schopf RE, Aust H, Knop J. 2002. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infl iximab. J Am Acad Dermatol, 46:886-91
56. Setoguchi S, Solomon DH, Weinblatt ME, et al. 2006. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum, 54:2757-64
57. Shear NH. 2006. Fulfi lling an unmet need in psoriasis: do biologicals hold the key to improved tolerability? Drug Saf, 29:49-66
58. Smith CH, Jackson K, Bashir SJ, et al. 2006. Infl iximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br J Dermatol, 155:160-9
59. Sri JC, Tsai CL, Deng A, et al. 2007. Osteomyelitis occurring during infl iximab treatment of severe psoriasis. J Drugs Dermatol, 6:207-10
60. Straub RH, Härle P, Sarzi-Puttini P, et al. 2006. Tumor necrosis factor-neutralizing therapies improve altered hormone axes: an alternative mode of antiinfl ammatory action. Arthritis Rheum, 54:2039-46
61. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. 2002. Infl iximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut, 50:206-11
62. Torre-Amione G, Kapadia S, Lee J, et al. 1996. Tumor necrosis factoralpha and tumor necrosis factor receptors in the failing human heart. Circulation, 93:704-11
63. Turbitt ML, Akhurst RJ, White SI, et al. 1990. Localization of elevated transforming growth factor-alpha in psoriatic epidermis. J Investig Dermatol, 95:229-32
64. Wahie S, Alexandroff A, Reynolds NJ. 2006. Hepatitis: a rare, but important, complication of infl iximab therapy for psoriasis. Clin Exp Dermatol, 31:460-1
65. Wolfe F, Michaud K. 2007. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum, 56:2886-95
66. Woolacott NF, Khadjesari ZC, Bruce IN, et al. 2006. Etanercept and infl iximab for the treatment of psoriatic arthritis: a systematic review. Clin Exp Rheumatol, 24:587-93